Delivery Order SPE2DB22D1106-SPE2DB25FFBS2
- Not listed
- The Defense Logistics Agency (DLA) awarded a $37,466.05 firm fixed price delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with an ultimate completion date of August 1, 2025. This non-set-aside competitive award was issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1 billion through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $36,245.57 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order was placed under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $31,715.77 by the Defense Logistics Agency on July 22, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed price contract carries an ultimate completion date of July 23, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The...
- The Defense Logistics Agency awarded a delivery order totaling $40,340.72 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 tablets per unit. This firm fixed price delivery order, valued at $16,263.11, represents a non-competitive set-aside award and is scheduled for completion by August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $5,533.31 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $17,897.96 to AmerisourceBergen Drug Corp for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded and scheduled for completion by July 25, 2025. The award represents a pharmaceutical supply order under AmerisourceBergen's larger contract vehicle with DLA Troop Support Medical, which serves as the primary mechanism for...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a competitively awarded delivery order from the Defense Logistics Agency valued at $51,148.62 for Biktarvy 50-200-25 mg tablets (30-count units). The contract is a firm fixed price delivery order with a completion date of July 29, 2025, and was awarded on July 28, 2025. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order valued at $33,016.79 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price contract represents a non-compete award and is performed at the awardee's location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationship with the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,548.16 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The order was placed to...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFBS2Delivery Order
The Defense Logistics Agency awarded a $37,866.05 delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically BIKTARVY 50-200-25 mg tablets (30-count units), with a firm fixed price contract type. This delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 6, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026 that serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other military healthcare systems. The company has demonstrated significant capability in fulfilling diverse federal pharmaceutical requirements, with its DLA portfolio encompassing specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The current award for BIKTARVY, an antiretroviral medication used in HIV treatment, exemplifies AmerisourceBergen's role in supplying essential pharmaceutical products to support military personnel and beneficiary healthcare needs through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $37.9k | 8/5/25 |